Re- PERFUSE:HFrEF患者における腎臓 perfusionに関する新しいリラクシン受容体アゴニストであるAZD3427のフェーズ1b試験
Marcin Ufnal1, Macarena P Quintana-Hayashi1, Kathleen Connolly1
1Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Stockholm, Sweden.
ESC heart failure
|September 4, 2025
まとめ
この研究は,AZD3427を調査しています.
科学分野:
- 心臓病科
- 腎臓科
- 薬理学について
背景:
- 心不全 (HF) と腎不全はしばしば共存し,患者のアウトカムを悪化させる.
- 心臓と腎臓の機能不全を 治療する治療法が不可欠です
- AZD3427は,リラクシンアナログであり,HF患者における心臓出力と腎臓機能の改善に有望であることが示されています.
研究 の 目的:
- 射出分数 (HFrEF) と推定球球膜濾過率 (eGFR) が低下した心不全患者におけるAZD3427の腎輸液への影響を評価する.
- AZD3427が腎臓の血流と皮質の容量を改善することによって,球の濾過率 (GFR) を高めるかもしれないメカニズムを探求する.
主な方法:
- Re- PERFUSE試験は,ランダム化,ダブルブラインド,プラセボ対照試験である.
- HFrEFとeGFRが30−90mL/ min/ 1. 73m2であった患者はAZD3427またはプラセボの単回投与を受けた.
- 治療前と後の腎皮質の血流を測定するために [15O]ラベルを貼った水でポジトロン放出トモグラフィー (PET) を用いた.
主要な成果:
- この研究は,腎皮質の血流の変化を評価し,全体的および焦点的変化を区別することを目的としています.
- 腎臓の潜在的増殖と 濾過膜の面積の増加に関する洞察を 提供することを目的としています
- AZD3427の安全性と耐受性は監視されます.
結論:
- この研究は,AZD3427の心臓と腎臓の双重効果を評価する.
- 併発性HFと腎不全の管理のための将来の治療戦略を参考にすることができます.
- AZD3427の効果を確認するためにさらなる研究が進行中です.
さらに関連する動画
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:29Heart Failure II: Pathophysiology
33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:25Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483